51³Ô¹ÏÍø

Tag - daiichi-sankyo

 
 

DAIICHI SANKYO

"The next five years are critical in defining Daiichi Sankyo¡¯s future,¡± CEO Hiroyuki Okuzawa said Tuesday.
BUSINESS / Companies
May 12, 2026
Daiichi Sankyo bets on new cancer drugs to fuel future growth
The Japanese drugmaker aims to more than double oncology revenue to above ?2.3 trillion by 2030 and become one of the world¡¯s top five oncology players by 2035.
Japan¡¯s panel of experts has cleared Daiichi Sankyo¡¯s vaccine for measles, mumps and rubella for ministerial approval. If approved, it will become the country¡¯s only available MMR vaccine, primarily intended for children.
51³Ô¹ÏÍø / Science & Health
Mar 3, 2026
Japan expert panel OKs Daiichi Sankyo¡¯s MMR vaccine
If approved by the minister, the vaccine, primarily for children, will be the sole MMR vaccine available in Japan.
Over-the-counter sales of emergency contraceptive pill Norlevo will begin in February.
51³Ô¹ÏÍø / Science & Health
Dec 18, 2025
Japan to start OTC sales of emergency contraception in February
Daiichi Sankyo¡¯s drug, Norlevo, will mark the first time such a pill will be available without a prescription in Japan.
AstraZeneca and Daiichi Sankyo's drug Datroway extended survival in patients with a hard-to-treat form of breast cancer.
BUSINESS / Companies
Oct 7, 2025
Breast cancer patients lived longer on drug Datroway, says maker
The drug is said to have significantly improved survival and delayed disease progression in patients with a particularly hard to treat form of the disease.
AstraZeneca and Daiichi Sankyo¡¯s Datroway breast cancer treatment, which the companies expect will eventually become a blockbuster, was recommended for approval in the European Union.
BUSINESS
Jan 31, 2025
AstraZeneca and Daiichi¡¯s breast cancer drug gets EU backing
The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in the U.S. and Japan.
The U.S. Food and Drug Administration's approval of novel breast cancer treatment by Daiichi Sankyo and AstraZeneca led Daiichi Sankyo's shares to post the largest intraday gain since August on Monday.
BUSINESS / Companies
Jan 20, 2025
Daiichi Sankyo rises most in five months on cancer drug approval
Datroway, developed with AstraZeneca, has been approved for patients with advanced breast tumors.
Daiichi Sankyo's headquarters in Tokyo
BUSINESS
Jan 18, 2025
AstraZeneca and Daiichi Sankyo win U.S. approval for breast cancer drug
The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain genetic signature.
Keisuke Yoshida, a former Daiichi Sankyo employee, was sentenced to 16 years in prison on Wednesday for murdering his wife with methanol in 2022.
51³Ô¹ÏÍø / Crime & Legal
Oct 31, 2024
Ex-employee of drugmaker sentenced to 16 years for methanol murder
Tokyo District Court on Wednesday sentenced a former employee of drugmaker Daiichi Sankyo to 16 years in prison for the murder of his wife by methanol poisoning in 2022.
The Tokyo District Court
51³Ô¹ÏÍø / Crime & Legal
Oct 11, 2024
Ex-Daiichi Sankyo employee faces 18 years for allegedly poisoning wife
The indictment states that Keisuke Yoshida intentionally poisoned his 40-year-old wife, Yoko, by having her ingest methanol at their home in Tokyo.
Hiroyuki Okuzawa, chief operating officer of Daiichi Sankyo, during an interview in Tokyo on Friday
BUSINESS / Companies
Oct 11, 2024
Daiichi Sankyo eyes newer cancer drugs to stave off rivals
The Japanese drugmaker has emerged as a leader in ADC, a type of cancer therapy that targets cancerous cells while sparing the healthy ones.
Daiichi Sankyo is working on the next generation of targeted cancer drugs.
51³Ô¹ÏÍø / Science & Health
Sep 17, 2024
Daiichi wants to go it alone in search for targeted cancer drugs
Investors are betting on Daiichi¡¯s continued success, with its share price up 122% in the last five years.
Keisuke Yoshida, 42, is accused of killing his wife by poisoning her with methanol at their home in Tokyo¡¯s Ota Ward between Jan. 14 and 15 in 2022.
51³Ô¹ÏÍø / Crime & Legal
Sep 2, 2024
Ex-employee of Daiichi Sankyo denies poisoning his wife with methanol
Keisuke Yoshida, formerly a senior researcher at the pharmaceutical firm, said he had never thought of killing his wife.
Health minister Keizo Takemi fields questions from reporters in March after a Cabinet meeting to deal with health problems caused by Kobayashi Pharmaceutical's beni k¨­ji red yeast rice supplements.
51³Ô¹ÏÍø / Science & Health
Aug 14, 2024
Health Minister Keizo Takemi on how to improve Japan¡¯s health care system
Digitalization, hiring high-skilled foreign workers and increasing wages are among the steps that Japan could take.
In the past 11 months, health minister Keizo Takemi has been charting his own path, seeking to make Japan's health care policies more global and digitalized.
51³Ô¹ÏÍø / Science & Health
Aug 14, 2024
Global mindset crucial for reform of Japan¡¯s health care, minister says
International strategies and domestic health care reform are inextricably linked, says health minister Keizo Takemi.
51³Ô¹ÏÍø / Science & Health
Nov 28, 2023
Japan approves first domestically developed COVID-19 XBB vaccine
The XBB-adapted coronavirus vaccine will be available as a booster under the nation¡¯s free COVID-19 vaccination program beginning next week.
Daiichi Sankyo is aiming for at least ?900 billion of revenue from its oncology business in the fiscal year ending in March 2026.
BUSINESS
Oct 20, 2023
Merck signs $5.5 billion deal with Daiichi for cancer therapy development
Daiichi Sankyo is aiming for at least ?900 billion of revenue from its oncology business in the fiscal year ending in March 2026.
51³Ô¹ÏÍø / Science & Health
Aug 1, 2023
Japan panel endorses first domestically developed COVID vaccine
The shot is based on the original strain of the coronavirus, making it unlikely that it will be used in Japan or elsewhere.
Japan Times
BUSINESS / Companies
Jun 7, 2023
AstraZeneca¡¯s Japan partner to go solo on future cancer drugs
Daiichi Sankyo is expanding its sales and development staff overseas, aiming to boost production capacity so that it can handle its cancer drugs business entirely on its own.
Japan Times
BUSINESS
Jan 13, 2023
Japan¡¯s Daiichi Sankyo applies for approval of mRNA COVID vaccine
An approval would give Japan a homegrown mRNA vaccine ¡ª a vaccine type that has played a dominant role in the country¡¯s COVID-19 inoculation drive to this point.
Japan Times
51³Ô¹ÏÍø / Science & Health
Nov 15, 2022
Japan¡¯s Daiichi Sankyo says mRNA COVID vaccine successful in booster trial
Approval would give Japan a home-grown source for mRNA vaccines, which have made up the bulk of its COVID-19 inoculations to date.

Longform

For many people, utility poles and power lines have become such a familiar part of Japan¡¯s landscape that they often go unnoticed.
Why Japan¡¯s utility poles won¡¯t be disappearing anytime soon

SUSTAINABLE 51³Ô¹ÏÍø